Friday, July 06, 2018 11:30:57 AM
ONCE:
Today seemed like a good day to go short (my first ever who knows maybe my last ever too
). Just a small short position and I bought a few (very small) # of puts yesterday (spread is too big to get a decent amount).
There can be a few good things (from ONCE's perspective) from their Hemophilia A program (Higher factor levels, more consistent individual and within cohort #'s) but with the appreciation in stock price, I think a good part of that seems to be priced in. Probably if BMRN has a serious setback would be a bigger plus for their A program.
On Hemophilia B (which they only have a share of with PFE collaboration) they now seem to be lacking an advantage over Uniqure (time wise and potentially efficacy wise as well). Anyway, I don't intend to hold my short position that long. I see playing QURE vs ONCE Hemophilia B as an argument much further down the road.
The earlier stage pipeline is actually what I find most intriguing from a long investment standpoint (Pompe, CLN2 and Huntington's) and why I would considering going long at much, much lower prices since they are very early still.
Today seemed like a good day to go short (my first ever who knows maybe my last ever too
). Just a small short position and I bought a few (very small) # of puts yesterday (spread is too big to get a decent amount). There can be a few good things (from ONCE's perspective) from their Hemophilia A program (Higher factor levels, more consistent individual and within cohort #'s) but with the appreciation in stock price, I think a good part of that seems to be priced in. Probably if BMRN has a serious setback would be a bigger plus for their A program.
On Hemophilia B (which they only have a share of with PFE collaboration) they now seem to be lacking an advantage over Uniqure (time wise and potentially efficacy wise as well). Anyway, I don't intend to hold my short position that long. I see playing QURE vs ONCE Hemophilia B as an argument much further down the road.
The earlier stage pipeline is actually what I find most intriguing from a long investment standpoint (Pompe, CLN2 and Huntington's) and why I would considering going long at much, much lower prices since they are very early still.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
